Although CSL Behring’s Hizentra (IgPro20) is touted as a key pipeline agent to watch, rheumatologists currently prefer AstraZeneca’s Saphnelo (anifrolumab),…
7 October 2024
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
AstraZeneca has entered into an exclusive…